2008 has seen no decrease in the opportunities available for outsourcing drug discovery, for a number of reasons. New technologies increase the number of targets and accelerate the identification of active compounds. There is increasing pressure to develop new lead compounds due to the near-term loss of patent protection for many drug product. And there is also pressure to reduce the time spent in drug discovery and to bring drugs to market sooner, as well as the ever-present cost considerations.

Kalorama Information's Outsourcing in Drug Discovery offers unparalleled discussion of the drug discovery outsourcing market. It presents viewpoints from both customers and suppliers. Segments, size, and growth of the market are presented. The trend toward the increased use of offshore suppliers is covered in detail. The report also provides profiles of 23 suppliers, representative of those active in this market.

Segments covered in this report include:

• Chemistry Services
  • Building Blocks
  • Compound Synthesis
  • Libraries
  • Process Research
  • Other Services

• Biology Services
  • Protein Expression
  • Structural Analysis
  • Target Validation
  • Pathways Analysis
  • Other Services

• Screening Services
  • Assay Development
  • Primary Screening
  • Secondary Screening

• Lead Optimization
  • Early ADMET
  • Analogues Creation
  • Computational Support
  • Other services

In addition to market data and forecasts, the report covers issues such as:

• What factors should a client consider when deciding whether to do a project in-house or outsource it?
• Is it in the client's best interest to seek a domestic outsourcing partner, or go with an overseas supplier?
• How does the client select the CRO that is best for him?
• What are the best practices when working with a CRO?
• How do you measure his effectiveness?
• How do you avoid problems with your CRO?
• How do you maximize benefits?

This report looks offshore at outsourcing suppliers based in three major areas: India, China, and Eastern Europe. The relative advantages each country provides are contrasted with some of their limitations. The report asses which projects are moving to which suppliers and why.

Related Reports:

Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
May 11, 2012 - KLI3889488 - $3,995.00

World Market for Anti-Infectives: Antifungals, Antibacterials and Antivirals (Treatments for HIV, HBV, HCV, Urinary Tract, Respiratory, Candidiasis and Other Infections)
Feb 1, 2012 - KLI6772957 - $3,800.00

Vaccine Production (Trends, Techniques, Key Players, Spending Estimates and Forecasts)
Feb 1, 2012 - KLI6420063 - $2,500.00

Stem Cells: Worldwide Markets for Transplantation and Cord Blood Banking (Projections for Stem Cell Use in Cancer, Alzheimer’s, Diabetes, Arthritis and Other Diseases)
Jan 1, 2012 - KLI6490034 - $3,995.00

Outsourcing in Drug Development: The Contract CRO, Clinical Trial Lab and EDC Market
Jan 1, 2012 - KLI6687130 - $3,995.00

The World Market for Cancer Therapeutics and Biotherapeutics (Chemotherapy Agents, Interleukins/interferons, Monoclonal Antibodies, Hormone and Other Therapies), 4th Edition
Jan 1, 2012 - KLI6501843 - $3,500.00

US Pharmaceutical, Medical Device, Diagnostics Markets
Dec 1, 2011 - KLI6077623 - $500.00

Vaccines 2011-15: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry
Jul 1, 2011 - KLI6277155 - $3,600.00

What's Next in Biopharmaceuticals? (mAbs, rDNA, Interferons, and Other Upcoming Biologic Drugs) 2011-2015
May 1, 2011 - KLI6329805 - $2,995.00

Asian Vaccine Markets: India, China, Japan, Korea, Indonesia and Rest of Asia
Mar 25, 2011 - KLI6205711 - $3,500.00